US2011206715A1PendingUtilityA1

Molecular differences between species of the m. tuberculosis complex

60
Assignee: UNIV LELAND STANFORD JUNIORPriority: Aug 25, 1998Filed: Apr 2, 2010Published: Aug 25, 2011
Est. expiryAug 25, 2018(expired)· nominal 20-yr term from priority
Inventors:Marcel BehrPeter SmallGary SchoolnikMichael A. Wilson
C12Q 1/689A61P 31/00A61P 37/04A61P 31/06C12Q 2600/156
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb. isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be reintroduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.

Claims

exact text as granted — not AI-modified
1 . An immunogenic composition, comprising:
 a substantially pure polypeptide encoded by a nucleotide sequence comprising the open reading frame Rv2653, SEQ ID NO:93 or a polypeptide encoded by a nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:93 or where said polypeptide is fused to another peptide or protein; and a pharmaceutically acceptable excipient.   
     
     
         2 . The immunogenic composition according to  claim 1 , further comprising an adjuvant. 
     
     
         3 . The immunogenic composition according to  claim 1 , wherein said polypeptide is fused to another peptide or protein. 
     
     
         4 . The immunogenic composition according to  claim 1 , comprising a  mycobacterium  of the  M. tuberculosis  complex that has been modified by introduction of said nucleotide sequence comprising the open reading frame Rv2653 (SEQ ID NO:93) or nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:93. 
     
     
         5 . The immunogenic composition according to  claim 4 , wherein said  mycobacterium  of the  M. tuberculosis  complex is  bacillus  Calmette-Guerin. 
     
     
         6 . The immunogenic composition according to  claim 4 , wherein said  mycobacterium  of the  M. tuberculosis  complex is  M. bovis.    
     
     
         7 . The immunogenic composition according to  claim 1 , wherein said polypeptide is co-formulated with a  mycobacterium  of the  M. tuberculosis  complex. 
     
     
         8 . The immunogenic composition of  claim 7 , wherein said  mycobacterium  of the  M. tuberculosis  complex is  bacillus  Calmette-Guerin. 
     
     
         9 . The immunogenic composition according to  claim 7 , wherein said  mycobacterium  of the  M. tuberculosis  complex is  M. bovis.    
     
     
         10 . A method of immunizing an individual to  M. tuberculosis,  the method comprising:
 injecting said individual with a  mycobacterium  of the  M. tuberculosis  complex that has been modified to introduce a nucleotide sequence comprising the open reading frame Rv2653, SEQ ID NO:93 or a polypeptide encoded by a nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:9, wherein said  mycobacterium  of the  M. tuberculosis  complex is  bacillus  Calmette-Guerin.   
     
     
         11 . A method of immunizing an individual to  M. tuberculosis,  the method comprising:
 injecting said individual with a polypeptide encoded by a nucleotide sequence comprising the open reading frame Rv2653, SEQ ID NO:93 or a polypeptide encoded by a nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:9 or where said polypeptide is fused to another peptide or protein, wherein said polypeptide is co-formulated with  bacillus  Calmette-Guerin.   
     
     
         12 . A genetically altered  mycobacterium  of the  M. tuberculosis  complex, comprising an exogenous nucleic acid sequence comprising the open reading frame Rv2653, SEQ ID NO:93 or a polypeptide encoded by a nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:9. 
     
     
         13 . The genetically altered  mycobacterium  of  claim 12 , wherein said exogenous nucleic acid encodes a polypeptide that is fused to another peptide or protein. 
     
     
         14 . The genetically altered  mycobacterium  of  claim 12 , wherein said  mycobacterium  is BCG. 
     
     
         15 . The  mycobacterium  of  claim 12 , and a physiologically acceptable carrier for injection.

Join the waitlist — get patent alerts

Track US2011206715A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.